Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01164579 · ClinicalTrials.gov registry record · Phase 2
Effects of Tofacitinib (CP-690,550) on Magnetic Resonance Imaging (MRI)- Assessed Joint Structure In Early Rheumatoid Arthritis (RA)
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 109
- Enrollment target
NCT01164579 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 109 participants.
The verdict
NCT01164579, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 109 participants
- Enrollment target
Study Summary
Evaluation of efficacy and safety of tofacitinib (CP-690,550) for the treatment of early rheumatoid arthritis in adult patients with moderate to severe disease who are methotrexate naïve. The efficacy will be evaluated by exploring the effects on joint structure assessed by magnetic resonance imaging, x-rays and by standard clinical assessment.
Interventions
- DRUG Tasocitinib plus Methotrexate
- DRUG Tofacitinib plus placebo methotrexate
- DRUG Placebo tofacitinib plus Methotrexate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 109 participants |
| Start Date | 2010-10 |
| Est. Completion | 2013-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01164579
The ClinicalTrials.gov registry entry for NCT01164579 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 109 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Tasocitinib plus Methotrexate is the first listed.
NCT01164579 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01164579 about?
NCT01164579 is a clinical study titled "Effects of Tofacitinib (CP-690,550) on Magnetic Resonance Imaging (MRI)- Assessed Joint Structure In Early Rheumatoid Arthritis (RA)". Evaluation of efficacy and safety of tofacitinib (CP-690,550) for the treatment of early rheumatoid arthritis in adult patients with moderate to severe disease who are methotrexate naïve. The efficacy will be evaluated by exploring the effects on joint structure assessed by magnetic resonance imagin...
What is the current status of trial NCT01164579?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 109 participants. The study started on 2010-10. Estimated completion is 2013-11.
What interventions are being tested in trial NCT01164579?
The interventions under investigation include: Tasocitinib plus Methotrexate (DRUG), Tofacitinib plus placebo methotrexate (DRUG), Placebo tofacitinib plus Methotrexate (DRUG).
Who is sponsoring clinical trial NCT01164579?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.